跳至主要内容
临床试验/NCT04317053
NCT04317053已完成不适用

Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program

NYU Langone Health2 个研究点 分布在 1 个国家目标入组 253 人开始时间: 2020年10月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
253
试验地点
2
主要终点
Number of Opioid-related Adverse Events

研究概览

简要总结

The New York City (NYC) Department of Health and Mental Hygiene (DOHMH) has implemented Relay, a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. The proposed randomized controlled trial will evaluate the impact of Relay on preventing subsequent opioid-related adverse events. A total of 350 eligible individuals with nonfatal opioid OD presenting to one of four participating EDs will be enrolled and randomized to one of two arms: 1) site-directed care (SDC) or 2) Relay-peer-delivered OD education and treatment linkage, including 90 days of peer navigation. Outcomes will be measured for 12 months through interviews and administrative health data.

详细描述

Relay is a novel program that engages and intervenes with individuals in the ED following an opioid OD and for the next 90 days, with the goal of preventing subsequent OD events. Relay is delivered by trained peer navigators, who are DOHMH staff with lived substance use experience. Relay navigators provide counseling, linkage to services, and OD prevention education.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (≥18 years)
  • English- or Spanish-speaking
  • Patient at a participating ED with nonfatal opioid OD.
  • Currently residing in NYC

排除标准

  • Unable to provide informed consent
  • Currently incarcerated, currently living in another controlled environment prohibiting research contacts, or currently in police custody
  • Known to be currently pregnant
  • Already participating in the study (patients will only be enrolled into the study once)
  • Already actively engaged in the Relay program (within the 90-day program window)
  • Speaks only Spanish, at a site and time period when no Spanish-speaking RA is available

结局指标

主要结局

Number of Opioid-related Adverse Events

时间窗: Up to Month 12

Opioid-related adverse events includes fatal and non-fatal opioid-involved overdose as well as substance use-related emergency department (ED) visits. ED visits and fatal overdoses in the 12-month period after baseline will be captured in administrative data sources. Other non-fatal opioid-involved overdose events will be captured by self-report in follow-up interviews through six months after baseline, and estimated for the second half of the 12-month follow-up period.

次要结局

  • Number of Participants Who Initiate Medication for Opioid Use Disorder (MOUD)(Up to Month 3)
  • Overdose Risk Behavior Questionnaire Score(Month 6)
  • Time to Next Opioid-Involved Overdose(Up to Month 6)
  • Number of Emergency Deparment (ED) Visits for Any Cause(Up to Month 12)
  • Number of ED Visits for Other (Non-OD) Substance Use Reasons(Up to Month 12)
  • Number of Opioid Overdose-Related ED Visits(Up to Month 12)
  • Percentage of Participants Who Self-Report Opioid-Involved Overdose(Month 6)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
4 期
A randomized, multicentre, double-blind, parallel, sham-controlled study of the gammaCore®, a non-invasive neurostimulator device for the acute relief of episodic and chronic cluster headache.cluster headaches10019231
NL-OMON40599electroCore LLC35
已完成
不适用
Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot UlcersDiabetic Foot Ulcers
NCT02880592Organogenesis89
已完成
2 期
A randomized, open-label, parallel-group, multi-center study of adding edoxaban or clopidogrel to aspirin to maintain patency in subjects with peripheral arterial disease following femoropopliteal endovascular intervention-edoxaban in peripheral arterial disease (ePAD)narrowing of the peripheral arteries (mostly in the legs)periferal arterial disease10003216
NL-OMON40071Daiichi Sankyo Development Ltd14
已完成
3 期
A Multicenter Randomized Controlled Trial to Compare the Efficacy of End-ischemic Dual Hypothermic Oxygenated Perfusion with Standard Static Cold Storage of Liver Grafts Donated after Circulatory Death in Preventing Non-anastomotic Biliary Strictures after TransplantatioEnd-stage liver disease100179431001965410019818
NL-OMON47263niversitair Medisch Centrum Groningen120
已完成
3 期
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)ALSAmyotrophic Lateral Sclerosis10011305
NL-OMON44970AB Science10
Multi-Center Randomized Controlled Trial of Relay-... | 临床试验